| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 05/18/2000 | CA2350071A1 Use of propionyl l-carnitine for the preparation of a medicament capable of inducing apoptosis |
| 05/18/2000 | CA2350062A1 Combinations comprising a beta-agonist and a further antidiabetic agent |
| 05/18/2000 | CA2349951A1 Platelet-derived growth factor d, dna coding therefor, and uses thereof |
| 05/18/2000 | CA2349814A1 Cytokine signal regulators |
| 05/18/2000 | CA2349700A1 Therapeutic polymorphs of a gaba-a alpha-5 inverse agonist and pamoate formulations of the same |
| 05/18/2000 | CA2349592A1 Use of gm-csf to inhibit development of drug resistance in hiv+ patients |
| 05/18/2000 | CA2349498A1 Methods and compositions for treating or preventing peripheral neuropathies |
| 05/18/2000 | CA2349449A1 Cell surface glycoproteins |
| 05/18/2000 | CA2348900A1 Disposable premoistened wipe containing an antimicrobial protease inhibitor |
| 05/18/2000 | CA2348885A1 Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease |
| 05/18/2000 | CA2348763A1 Novel compounds and medicinal use thereof |
| 05/18/2000 | CA2347916A1 Inhibition of the formation of vascular hyperpermeability |
| 05/18/2000 | CA2318162A1 Oxy-vanadium (iv) complexes having spermicidal activity |
| 05/17/2000 | EP1001025A2 Outer membrane proteins from actinobacillus pleuropneumoniae |
| 05/17/2000 | EP1001023A2 Frizzled-4, a putative Wnt-receptor |
| 05/17/2000 | EP1000626A1 Chemokine receptor antagonist and cyclosporin in combined therapy |
| 05/17/2000 | EP1000617A2 Treatment of platelet derived growth factor related disorders such as cancers using inhibitors of platelet derived growth receptor |
| 05/17/2000 | EP1000614A1 Sucralfate-containing composition and process for the preparation thereof |
| 05/17/2000 | EP1000082A2 Antigen binding fragments, designated 4b5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers |
| 05/17/2000 | EP1000051A1 Carbamyloxy compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 05/17/2000 | EP1000029A1 (+)-norcisapride useful for 5-ht3 and 5-ht4 mediated disorders |
| 05/17/2000 | EP1000012A1 Process for converting propargylic amine-n-oxides to enaminones |
| 05/17/2000 | EP0999854A1 Switchable viscoelastic systems containing galactomannan polymers and borate |
| 05/17/2000 | EP0999850A2 Methods and compositions for regulating nuclear trafficking of proteins |
| 05/17/2000 | EP0999847A1 Health supplement |
| 05/17/2000 | EP0999845A1 Treatment of diabetes with thiazolidinedione and sulphonylurea |
| 05/17/2000 | EP0999840A1 Use of draflazine-analogues for treating pain |
| 05/17/2000 | EP0999839A1 Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches |
| 05/17/2000 | EP0999835A1 Imidazole derivatives as mdr modulators |
| 05/17/2000 | EP0999825A1 Ophthalmic compositions containing galactomannan polymers and borate |
| 05/17/2000 | EP0871437B1 Use of boswellic acid for treating brain tumours |
| 05/17/2000 | EP0831767A4 Alpha hydroxyacid esters for skin aging |
| 05/17/2000 | EP0804191B1 Use of inhibitors of platelet derived growth receptor for the manufacture of a medicament for the treatment of cancers |
| 05/17/2000 | EP0726768B1 Use of nitric oxide releasing compounds for the manufacture of a medicament for protection in ischemia reperfusion injury |
| 05/17/2000 | CN1253586A Compositions and methods for diagnosing/treating disease based on beta-catenin/transcription actor interactions |
| 05/17/2000 | CN1253559A Sulfonyl divalent aryl alpha-hydroxamic acid compounds |
| 05/17/2000 | CN1253508A Topical nasal antiinflammatory compositions |
| 05/17/2000 | CN1253504A Cytokine related treatments of disease |
| 05/17/2000 | CN1253474A Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds |
| 05/17/2000 | CN1253022A Composition used to enhance permeability of skin medicament |
| 05/16/2000 | US6063911 Methods and compositions for treatment of cell proliferative disorders |
| 05/16/2000 | US6063807 Cyclo-oxygenase inhibitor and amidine derivatives salts, preparation method therefor, use thereof as drugs, and pharmaceutical compositions containing said salts |
| 05/16/2000 | US6063797 γ-RAR antagonist ligand or α-RAR agonist ligand as an apoptosis inhibitor |
| 05/16/2000 | US6063776 Anticholesterol agents |
| 05/16/2000 | US6063628 Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA |
| 05/16/2000 | US6063610 Flea hydrolase enzyme; for development of antibodies to prevent parasitic infection of plant and animals |
| 05/16/2000 | US6063596 G-protein coupled receptors associated with immune response |
| 05/16/2000 | US6063594 DNA encoding a novel human anion channel |
| 05/16/2000 | US6063407 Treatment of vascular thrombosis and restenosis with inhaled nitric oxide |
| 05/16/2000 | US6063400 Targeted liposomal constructs for diagnostic and therapeutic uses |
| 05/16/2000 | US6063395 Sustained rlease |
| 05/16/2000 | US6063373 Enhanced activation of NK cells using an NK cell activator and a hydrogen peroxide scavenger or inhibitor |
| 05/16/2000 | CA2271826A1 Methods and compositions for increasing the infectively of retroviruses |
| 05/16/2000 | CA2170255C Pharmaceutical composition for immunoenhancement therapy |
| 05/16/2000 | CA1340994C Treatment of conditions and disease |
| 05/12/2000 | CA2288680A1 Modulation of cell proliferative disorders by cyclic rgd |
| 05/11/2000 | WO2000026372A1 Myosin heavy chain homolog |
| 05/11/2000 | WO2000026370A2 Adenine nucleotide translocator (ant) fusion proteins and uses thereof |
| 05/11/2000 | WO2000026348A2 Mammalian subtilisin/kexin isozyme ski-1: a proprotein convertase with a unique cleavage specificity |
| 05/11/2000 | WO2000026246A2 Crystallized form of fc epsilon receptor alpha chain, its 3-d model and uses thereof |
| 05/11/2000 | WO2000026243A2 Transmembrane 4 proteins |
| 05/11/2000 | WO2000026238A2 Biological materials and methods useful in the diagnosis and treatment of prion diseases |
| 05/11/2000 | WO2000026236A2 Method of modulating cell differentiation or neoplastic transformation by altering cadherin-11 expression or function |
| 05/11/2000 | WO2000026197A1 Novel inhibitors of impdh enzyme |
| 05/11/2000 | WO2000025829A2 Radiodense compositions |
| 05/11/2000 | WO2000025819A1 Enhanced radiation therapy |
| 05/11/2000 | WO2000025808A1 Inhibition of differentiation of cytotoxic t-cells by p-selectin ligand (psgl) antagonists |
| 05/11/2000 | WO2000025805A1 Vascular endothelial growth factor-like protein from orf virus nz2 binds and activates mammalian vegf receptor-2 |
| 05/11/2000 | WO2000025797A1 Combination therapy to treat hepatitis b virus |
| 05/11/2000 | WO2000025794A1 Uses of 1-amino-3-(n,n-dimethylamino)-propylidene-1,1-bisphosphonic acid |
| 05/11/2000 | WO2000025793A1 Compositions for the treatment and prevention of neurological and pathopsychological diseases |
| 05/11/2000 | WO2000025787A1 Pharmaceutical compositions containing poly(adp-ribose) glycohydrolase inhibitors and methods of using the same |
| 05/11/2000 | WO2000025786A1 Heterocyclic potassium channel inhibitors |
| 05/11/2000 | WO2000025783A1 Use of a nicotine receptor agonist in the treatment of obsessive compulsive disorder |
| 05/11/2000 | WO2000025779A1 Method of treating migraines and pharmaceutical compositions |
| 05/11/2000 | WO2000025778A1 5ht1 receptor agonists and metoclopramide for the treatment of migraine |
| 05/11/2000 | WO2000025776A1 Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use |
| 05/11/2000 | WO2000025774A1 Benzamide potassium channel inhibitors |
| 05/11/2000 | WO2000025773A1 Pharmaceutical combination of mildronate and enalapril |
| 05/11/2000 | WO2000025771A1 Method for preventing increased iridial pigmentation during prostaglandin treatment |
| 05/11/2000 | WO2000025770A1 Carbocyclic potassium channel inhibitors |
| 05/11/2000 | WO2000025764A2 Compositions for the treatment and prevention of cardiovascular diseases |
| 05/11/2000 | WO2000025754A2 Solid oral dosage forms containing alginic acid and famotidine |
| 05/11/2000 | WO2000025723A2 Methods and compositions for the prevention of tolerance to medications |
| 05/11/2000 | WO2000025601A1 Energetic rehydration fluid composition in particular for young animals no longer able to digest milk normally |
| 05/11/2000 | WO2000009110A3 N-linked urea or carbamate of heterocyclic thioesters for vision and memory disorders |
| 05/11/2000 | WO2000009099A3 Treatment of vasodilatory headache |
| 05/11/2000 | WO2000007618A3 Anti-apoptotic compositions comprising the r1 subunit of herpes simplex virus ribonucleotide reductase or its n-terminal portion; and uses thereof |
| 05/11/2000 | WO2000007581A3 Antioxidant, antiproliferous composition, comprising a carnitine and a carotenoid |
| 05/11/2000 | WO2000007543A3 Conjugates targeted to the interleukin-2 receptors |
| 05/11/2000 | WO2000007542A3 Utilization of aryl(or heteroaryl)azolylcarbinol derivatives in the preparation of a medicament for the treatment of troubles mediated by an excess of substance p |
| 05/11/2000 | WO2000006769A3 Human ccr-2 gene polymorphisms |
| 05/11/2000 | CA2350052A1 Pharmaceutical compositions containing poly(adp-ribose) glycohydrolase inhibitors and methods of using the same |
| 05/11/2000 | CA2349444A1 Production of adenine nucleotide translocator (ant), novel ant ligands and screening assays therefor |
| 05/11/2000 | CA2349427A1 Method for preventing increased iridial pigmentation during prostaglandin treatment |
| 05/11/2000 | CA2349410A1 Crystallized form of fc epsilon receptor alpha chain, its 3-d model and uses thereof |
| 05/11/2000 | CA2349212A1 Myosin heavy chain homolog |
| 05/11/2000 | CA2348979A1 Method of treating migraines and pharmaceutical compositions |
| 05/11/2000 | CA2348751A1 Biological materials and methods useful in the diagnosis and treatment of diseases |
| 05/11/2000 | CA2348714A1 Energetic rehydration fluid composition in particular for young animals no longer able to digest milk normally |